A phase Ib/II study of onvansertib (PCM-075) in combination with FOLFIRI and bevacizumab for second-line treatment of metastatic colorectal cancer (mCRC) in patients with a KRAS mutation-MedSci.cn

A phase Ib/II study of onvansertib (PCM-075) in combination with FOLFIRI and bevacizumab for second-line treatment of metastatic colorectal cancer (mCRC) in patients with a KRAS mutation

Lenz, HJ; Ahn, DH; Ridinger, M; Erlander, MG; Barzi, A

JOURNAL OF CLINICAL ONCOLOGY, 2020; 38 (4):

科室
- - 订阅+
  - 更多科室
工具
服务